GSKGlaxoSmithKlineSigning up patients
A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer
Neoplasms, Colon
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 120 (planned)
- Started
- Feb 18, 2025
- Main results expected
- Nov 23, 2026
- Fully finished
- Oct 26, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Major pathological response (mPR) rate
Measured over: Up to approximately 18 weeks
Number of participants with adverse events (AEs), serious adverse events (SAEs), immune-mediated adverse events (imAEs), and AEs leading to death or discontinuation of study intervention
Measured over: Up to approximately 105 weeks
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06567782 · record last updated 2026-05-22 · checked 2026-11-09 15:47 UTC